Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
side by side viewer icon HTML

Abstract

Integral membrane proteins are attractive targets for therapeutic intervention due to their crucial roles in cellular functions and their involvement in various diseases. However, targeting these proteins for degradation has posed significant challenges due to their complex structures and diverse functions. The emergence of proteolysis-targeting chimeras (PROTAC) represents a groundbreaking paradigm shift in drug development, offering a novel approach to address the degradation of integral membrane proteins. This review explores the innovative application of PROTAC technology in inducing the degradation of integral membrane proteins. PROTACs are molecules that have two roles: they bring together specific target proteins and E3 ubiquitin ligases, which help with ubiquitination and the degradation of proteins by proteasomes. As PROTACs are made up of separate parts, they can be put together to make custom molecules that can target difficult targets, such as integral membrane proteins. This review covers recent developments and advancements in the design and optimisation of PROTACs tailored for integral membrane protein degradation. Furthermore, it also discusses the problems that come up when trying to target membrane proteins and how PROTACs solve these problems by using ligands that can pass cell membranes and specifically interact with target proteins. It delves into the potential therapeutic implications of degrading integral membrane proteins using PROTACs and elucidates the impact of this novel approach in treating diseases that involve aberrant membrane protein expression or function by highlighting specific examples and case studies.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X306297240726094157
2024-07-31
2025-03-01

  • From This Site

    /content/journals/cis/10.2174/012210299X306297240726094157
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. RenardK. ByrneB. Insights into the role of membrane lipids in the structure, function and regulation of integral membrane proteins.Int. J. Mol. Sci.20212216902610.3390/ijms2216902634445730
     [Google Scholar]
  2. HongH. Role of lipids in folding, misfolding and function of integral membrane proteins.Lipids in Protein MisfoldingBerlin, HeidelbergSpringerLink201513110.1007/978‑3‑319‑17344‑3_1
     [Google Scholar]
  3. SezginE. SchwilleP. Model membrane platforms to study protein-membrane interactionsMol. Membr. Biol.201229514415410.3109/09687688.2012.70049022831167
     [Google Scholar]
  4. ShenH.H. LithgowT. MartinL. Reconstitution of membrane proteins into model membranes: Seeking better ways to retain protein activities.Int. J. Mol. Sci.20131411589160710.3390/ijms1401158923344058
     [Google Scholar]
  5. SuetsuguS. KurisuS. TakenawaT. Dynamic shaping of cellular membranes by phospholipids and membrane-deforming proteins.Physiol. Rev.20149441219124810.1152/physrev.00040.201325287863
     [Google Scholar]
  6. MacKenzieK.R. Folding and stability of α-helical integral membrane proteins.Chem. Rev.200610651931197710.1021/cr040438816683762
     [Google Scholar]
  7. SchwarzD. KlammtC. KoglinA. LöhrF. SchneiderB. DötschV. BernhardF. Preparative scale cell-free expression systems: New tools for the large scale preparation of integral membrane proteins for functional and structural studies.Methods200741435536910.1016/j.ymeth.2006.07.00116938466
     [Google Scholar]
  8. KochB. YuH.G. Regulation of inner nuclear membrane associated protein degradation.Nucleus201910116918010.1080/19491034.2019.164459331313624
     [Google Scholar]
  9. SpeersA.E. WuC.C. Proteomics of integral membrane proteins--theory and application.Chem. Rev.200710783687371410.1021/cr068286z17683161
     [Google Scholar]
  10. ZhengJ. LiL. JiangH. Molecular pathways of mitochondrial outer membrane protein degradation.Biochem. Soc. Trans.20194751437144710.1042/BST2019027531652437
     [Google Scholar]
  11. ZhangL. GuoY. ZhangY. LiY. PeiY. ZhangM. Regulation of PIN-FORMED Protein Degradation.Int. J. Mol. Sci.202324184310.3390/ijms2401084336614276
     [Google Scholar]
  12. UlmschneiderM.B. SansomM.S.P. Di NolaA. Properties of integral membrane protein structures: Derivation of an implicit membrane potential.Proteins200559225226510.1002/prot.2033415723347
     [Google Scholar]
  13. KarU.K. SimonianM. WhiteleggeJ.P. Integral membrane proteins: Bottom-up, top-down and structural proteomics.Expert Rev. Proteomics201714871572310.1080/14789450.2017.135954528737967
     [Google Scholar]
  14. KangC. LiQ. Solution NMR study of integral membrane proteins.Curr. Opin. Chem. Biol.201115456056910.1016/j.cbpa.2011.05.02521684799
     [Google Scholar]
  15. KellyL. PieperU. EswarN. HaysF.A. LiM. Roe-ZurzZ. KroetzD.L. GiacominiK.M. StroudR.M. SaliA. A survey of integral α-helical membrane proteins.J. Struct. Funct. Genomics200910426928010.1007/s10969‑009‑9069‑819760129
     [Google Scholar]
  16. TiefenauerL. DemarcheS. Challenges in the development of functional assays of membrane proteins.Materials (Basel)20125112205224210.3390/ma5112205
     [Google Scholar]
  17. KleinV.G. BondA.G. CraigonC. LokeyR.S. CiulliA. Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity.J. Med. Chem.20216424180821810110.1021/acs.jmedchem.1c0149634881891
     [Google Scholar]
  18. MajeedS. AhmadA.B. SeharU. GeorgievaE.R. Lipid membrane mimetics in functional and structural studies of integral membrane proteins.Membranes (Basel)202111968510.3390/membranes1109068534564502
     [Google Scholar]
  19. RajarathnamK. RösgenJ. Isothermal titration calorimetry of membrane proteins — Progress and challenges.Biochim. Biophys. Acta Biomembr.201418381697710.1016/j.bbamem.2013.05.02323747362
     [Google Scholar]
  20. ZhaoL. ZhaoJ. ZhongK. TongA. JiaD. Targeted protein degradation: Mechanisms, strategies and application.Signal Transduct. Target. Ther.20227111310.1038/s41392‑022‑00966‑435379777
     [Google Scholar]
  21. OuC.Y. LinY.F. ChenY.J. ChienC.T. Distinct protein degradation mechanisms mediated by Cul1 and Cul3 controlling Ci stability in Drosophila eye development.Genes Dev.200216182403241410.1101/gad.101140212231629
     [Google Scholar]
  22. KahanaC. AsherG. ShaulY. Mechanisms of protein degradation: An odyssey with ODC.Cell Cycle20054111461146410.4161/cc.4.11.211516205122
     [Google Scholar]
  23. HochstrasserM. Ubiquitin-dependent protein degradation.Annu. Rev. Genet.199630140543910.1146/annurev.genet.30.1.4058982460
     [Google Scholar]
  24. FlickK KaiserP Protein degradation and the stress response.Semin Cell Dev Biol.201223551552210.1016/j.semcdb.2012.01.019
     [Google Scholar]
  25. ZhangS. MaoY. AAA+ ATPases in protein degradation: Structures, functions and mechanisms.Biomolecules202010462910.3390/biom1004062932325699
     [Google Scholar]
  26. TakaloM. SalminenA. SoininenH. HiltunenM. HaapasaloA. Protein aggregation and degradation mechanisms in neurodegenerative diseases.Am. J. Neurodegener. Dis.20132111423516262
     [Google Scholar]
  27. ChristiansonJ.C. JaroschE. SommerT. Mechanisms of substrate processing during ER-associated protein degradation.Nat. Rev. Mol. Cell Biol.2023241177779610.1038/s41580‑023‑00633‑837528230
     [Google Scholar]
  28. ChamberlainP.P. HamannL.G. Development of targeted protein degradation therapeutics.Nat. Chem. Biol.2019151093794410.1038/s41589‑019‑0362‑y31527835
     [Google Scholar]
  29. VarshavskyA. The ubiquitin system, autophagy, and regulated protein degradation.Annu. Rev. Biochem.201786112312810.1146/annurev‑biochem‑061516‑04485928654326
     [Google Scholar]
  30. TanidaI. Autophagosome formation and molecular mechanism of autophagy.Antioxid. Redox Signal.201114112201221410.1089/ars.2010.348220712405
     [Google Scholar]
  31. DingW.X. YinX.M. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome.Autophagy20084214115010.4161/auto.519017986870
     [Google Scholar]
  32. ToureM. CrewsC.M. Small‐molecule PROTACS: New approaches to protein degradation.Angew. Chem. Int. Ed.20165561966197310.1002/anie.20150797826756721
     [Google Scholar]
  33. CasementR BondA CraigonC CiulliA Mechanistic and structural features of PROTAC ternary complexes.Targeted Protein DegradationBerlin, HeidelbergSpringer Link202110.1007/978‑1‑0716‑1665‑9_5
     [Google Scholar]
  34. GuenetteR.G. YangS.W. MinJ. PeiB. PottsP.R. Target and tissue selectivity of PROTAC degraders.Chem. Soc. Rev.202251145740575610.1039/D2CS00200K35587208
     [Google Scholar]
  35. MaiH. ZimmerM.H. MillerT.F.III Exploring PROTAC cooperativity with coarse-grained alchemical methods.J. Phys. Chem. B2023127244645510.1021/acs.jpcb.2c0579536607139
     [Google Scholar]
  36. CaoC. HeM. WangL. HeY. RaoY. Chemistries of bifunctional PROTAC degraders.Chem. Soc. Rev.202251167066711410.1039/D2CS00220E35916511
     [Google Scholar]
  37. ZengS. HuangW. ZhengX. Liyan cheng ZhangZ. WangJ. ShenZ. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.Eur. J. Med. Chem.202121011298110.1016/j.ejmech.2020.11298133160761
     [Google Scholar]
  38. WangP. ZhouJ. Proteolysis targeting chimera [PROTAC]: A paradigm-shifting approach in small molecule drug discovery.Curr. Top. Med. Chem.201818161354135610.2174/156802661866618101010192230306871
     [Google Scholar]
  39. KoravovićM TasićG RmandićM MarkovićB. Photocontrollable PROTAC molecules – structure and mechanism of action.Arhiv za farmaciju202171316117610.5937/arhfarm71‑30785
     [Google Scholar]
  40. WengG. LiD. KangY. HouT. Integrative modeling of PROTAC-mediated ternary complexes.J. Med. Chem.20216421162711628110.1021/acs.jmedchem.1c0157634709816
     [Google Scholar]
  41. ErmondiG. Garcia-JimenezD. CaronG. Protacs and building blocks: The 2d chemical space in very early drug discovery.Molecules202126367210.3390/molecules2603067233525371
     [Google Scholar]
  42. WengG. ShenC. CaoD. GaoJ. DongX. HeQ. YangB. LiD. WuJ. HouT. PROTAC-DB: An online database of PROTACs.Nucleic Acids Res.202149D1D1381D138710.1093/nar/gkaa80733010159
     [Google Scholar]
  43. GongL. LiR. GongJ. NingX. SunJ. MaQ. ZhuC. YangY. LinK. LiY. ZhangQ. LiT. LinZ. Discovery of a miniaturized PROTAC with potent activity and high selectivity.Bioorg. Chem.202313610655610.1016/j.bioorg.2023.10655637105002
     [Google Scholar]
  44. AnZ. LvW. SuS. WuW. RaoY. Developing potent PROTACs tools for selective degradation of HDAC6 protein.Protein Cell201910860660910.1007/s13238‑018‑0602‑z30603959
     [Google Scholar]
  45. ChenY. TandonI. HeelanW. WangY. TangW. HuQ. Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation.Chem. Soc. Rev.202251135330535010.1039/D1CS00762A35713468
     [Google Scholar]
  46. LiuZ. HuM. YangY. DuC. ZhouH. LiuC. ChenY. FanL. MaH. GongY. XieY. An overview of PROTACs: A promising drug discovery paradigm.Mol Biomed2022314610.1186/s43556‑022‑00112‑036536188
     [Google Scholar]
  47. HeS. DongG. ChengJ. WuY. ShengC. Strategies for designing proteolysis targeting chimaeras (PROTACs).Med. Res. Rev.20224231280134210.1002/med.2187735001407
     [Google Scholar]
  48. RichingK.M. VastaJ.D. HughesS.J. ZoppiV. ManiaciC. TestaA. UrhM. CiulliA. DanielsD.L. Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation.Curr Res Chem Biol2021110000910.1016/j.crchbi.2021.100009
     [Google Scholar]
  49. LaiA.C. CrewsC.M. Induced protein degradation: An emerging drug discovery paradigm.Nat. Rev. Drug Discov.201716210111410.1038/nrd.2016.21127885283
     [Google Scholar]
  50. MaresA. MiahA.H. SmithI.E.D. RackhamM. ThawaniA.R. CryanJ. HaileP.A. VottaB.J. BealA.M. CapriottiC. ReillyM.A. FisherD.T. ZinnN. BantscheffM. MacDonaldT.T. VossenkamperA. DaceP. ChurcherI. BenowitzA.B. WattG. DenyerJ. Scott-StevensP. HarlingJ.D. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2.Commun. Biol.20203114010.1038/s42003‑020‑0868‑632198438
     [Google Scholar]
  51. GuoJ. LiuJ. WeiW. Degrading proteins in animals: “PROTAC”tion goes in vivo.Cell Res.201929317918010.1038/s41422‑019‑0144‑930770868
     [Google Scholar]
  52. HanX. WangC. QinC. XiangW. Fernandez-SalasE. YangC.Y. WangM. ZhaoL. XuT. ChinnaswamyK. DelpropostoJ. StuckeyJ. WangS. Discovery of ARD-69 as a highly potent proteolysis targeting chimera [PROTAC] degrader of androgen receptor [AR] for the treatment of prostate cancer.J. Med. Chem.201962294196410.1021/acs.jmedchem.8b0163130629437
     [Google Scholar]
  53. BondesonDP SmithBE BurslemGM BuhimschiAD HinesJ Jaime-FigueroaS WangJ HammanBD IshchenkoA CrewsCM Lessons in PROTAC design from selective degradation with a promiscuous warhead.Cell Chem Biol20182517887.e510.1016/j.chembiol.2017.09.010
     [Google Scholar]
  54. BondesonD.P. MaresA. SmithI.E.D. KoE. CamposS. MiahA.H. MulhollandK.E. RoutlyN. BuckleyD.L. GustafsonJ.L. ZinnN. GrandiP. ShimamuraS. BergaminiG. Faelth-SavitskiM. BantscheffM. CoxC. GordonD.A. WillardR.R. FlanaganJ.J. CasillasL.N. VottaB.J. den BestenW. FammK. KruidenierL. CarterP.S. HarlingJ.D. ChurcherI. CrewsC.M. Catalytic in vivo protein knockdown by small-molecule PROTACs.Nat. Chem. Biol.201511861161710.1038/nchembio.185826075522
     [Google Scholar]
  55. HuZ. CrewsC.M. Recent developments in PROTAC‐mediated protein degradation: From bench to clinic.ChemBioChem2022232e20210027010.1002/cbic.20210027034494353
     [Google Scholar]
  56. BékésM. LangleyD.R. CrewsC.M. PROTAC targeted protein degraders: The past is prologue.Nat. Rev. Drug Discov.202221318120010.1038/s41573‑021‑00371‑635042991
     [Google Scholar]
  57. ParkerCG GalmozziA WangY CorreiaBE SasakiK JoslynCM KimAS CavallaroCL LawrenceRM JohnsonSR Ligand and target discovery by fragment-based screening in human cells.Cell20171683527541.e2910.1016/j.cell.2016.12.029
     [Google Scholar]
  58. BurslemG.M. CrewsC.M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery.Cell2020181110211410.1016/j.cell.2019.11.03131955850
     [Google Scholar]
  59. SchneiderM. RadouxC.J. HerculesA. OchoaD. DunhamI. ZalmasL.P. HesslerG. RufS. ShanmugasundaramV. HannM.M. ThomasP.J. QueisserM.A. BenowitzA.B. BrownK. LeachA.R. The PROTACtable genome.Nat. Rev. Drug Discov.2021201078979710.1038/s41573‑021‑00245‑x34285415
     [Google Scholar]
  60. KawadaI. SoejimaK. Screening of epidermal growth factor receptor mutation in lung cancer.Kokyu To Junkan200856617622
     [Google Scholar]
  61. ChongC.R. JänneP.A. The quest to overcome resistance to EGFR-targeted therapies in cancer.Nat. Med.201319111389140010.1038/nm.338824202392
     [Google Scholar]
  62. HuangH.T. SeoH.S. ZhangT. WangY. JiangB. LiQ. BuckleyD.L. NabetB. RobertsJ.M. PaulkJ. DastjerdiS. WinterG.E. McLauchlanH. MoranJ. BradnerJ.E. EckM.J. Dhe-PaganonS. ZhaoJ.J. GrayN.S. MELK is not necessary for the proliferation of basal-like breast cancer cells.eLife20176e2669310.7554/eLife.2669328926338
     [Google Scholar]
  63. DuG. JiangJ. WuQ. HenningN.J. DonovanK.A. YueH. CheJ. LuW. FischerE.S. BardeesyN. ZhangT. GrayN.S. Discovery of a potent degrader for fibroblast growth factor receptor 1/2.Angew. Chem. Int. Ed.20216029159051591110.1002/anie.20210132833915015
     [Google Scholar]
  64. ZhangC. HanX.R. YangX. JiangB. LiuJ. XiongY. JinJ. Proteolysis targeting chimeras [PROTACs] of anaplastic lymphoma kinase.Eur. J. Med. Chem.201815130431410.1016/j.ejmech.2018.03.07129627725
     [Google Scholar]
  65. SharmaS.V. BellD.W. SettlemanJ. HaberD.A. Epidermal growth factor receptor mutations in lung cancer.Nat. Rev. Cancer20077316918110.1038/nrc208817318210
     [Google Scholar]
  66. ZhaoH.Y. YangX.Y. LeiH. XiX.X. LuS.M. ZhangJ.J. XinM. ZhangS.Q. Discovery of potent small molecule PROTACs targeting mutant EGFR.Eur. J. Med. Chem.202020811278110.1016/j.ejmech.2020.11278132883633
     [Google Scholar]
  67. LiZ. LinY. SongH. QinX. YuZ. ZhangZ. DongG. LiX. ShiX. DuL. ZhaoW. LiM. First small-molecule PROTACs for G protein-coupled receptors: Inducing 1A-adrenergic receptor degradation.Acta Pharm. Sin. B20201091669167910.1016/j.apsb.2020.01.01433088687
     [Google Scholar]
  68. BensimonA PizzagalliMD KartnigF DvorakV EssletzbichlerP WinterGE Superti-FurgaG Targeted degradation of SLC transporters reveals amenability of multi-pass transmembrane proteins to ligand-induced proteolysis..Cell Chem Biol2020276728739.e910.1016/j.chembiol.2020.04.003
     [Google Scholar]
  69. NabetB. RobertsJ.M. BuckleyD.L. PaulkJ. DastjerdiS. YangA. LeggettA.L. ErbM.A. LawlorM.A. SouzaA. ScottT.G. VittoriS. PerryJ.A. QiJ. WinterG.E. WongK.K. GrayN.S. BradnerJ.E. The dTAG system for immediate and target-specific protein degradation.Nat. Chem. Biol.201814543144110.1038/s41589‑018‑0021‑829581585
     [Google Scholar]
  70. QuX. LiuH. SongX. SunN. ZhongH. QiuX. YangX. JiangB. Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.Eur. J. Med. Chem.202121811332810.1016/j.ejmech.2021.11332833773286
     [Google Scholar]
  71. ZhaoH.Y. WangH.P. MaoY.Z. ZhangH. XinM. XiX.X. LeiH. MaoS. LiD.H. ZhangS.Q. Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands.J. Med. Chem.20226564709472610.1021/acs.jmedchem.1c0182735254067
     [Google Scholar]
  72. WangY. ZhouY. CaoS. SunY. DongZ. LiC. WangH. YaoY. YuH. SongX. LiM. WangJ. WeiM. YangG. YangC. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).Bioorg. Chem.202111110483310.1016/j.bioorg.2021.10483333839580
     [Google Scholar]
  73. ChenY. YuanX. TangM. ShiM. YangT. LiuK. DengD. ChenL. Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).Bioorg. Chem.202211910550810.1016/j.bioorg.2021.10550834959180
     [Google Scholar]
  74. BaiY. YingY. The post-translational modifications of Smurf2 in TGF-β signaling.Front. Mol. Biosci.2020712810.3389/fmolb.2020.0012832733916
     [Google Scholar]
  75. LyleC. RichardsS. YasudaK. NapoleonM.A. WalkerJ. ArinzeN. BelghasemM. VellardI. YinW. RavidJ.D. ZavaroE. AmraeiR. FrancisJ. PhatakU. RifkinI.R. RahimiN. ChitaliaV.C. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth.Sci. Rep.2019912025710.1038/s41598‑019‑56208‑131882749
     [Google Scholar]
  76. PaivaS.L. CrewsC.M. Targeted protein degradation: Elements of PROTAC design.Curr. Opin. Chem. Biol.20195011111910.1016/j.cbpa.2019.02.02231004963
     [Google Scholar]
  77. IshidaT. CiulliA. E3 ligase ligands for PROTACs: How they were found and how to discover new ones.SLAS Discov.202126448450210.1177/247255522096552833143537
     [Google Scholar]
  78. ZhaoZ. UkidveA. KimJ. MitragotriS. Targeting strategies for tissue-specific drug delivery.Cell2020181115116710.1016/j.cell.2020.02.00132243788
     [Google Scholar]
  79. ChangM. GaoF. PontigonD. GnawaliG. XuH. WangW. Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.J. Am. Chem. Soc.202314525141551416310.1021/jacs.3c0515937327395
     [Google Scholar]
  80. MichaelidesI.N. CollieG.W. E3 ligases meet their match: Fragment-based approaches to discover new E3 ligands and to unravel E3 biology.J. Med. Chem.20236653173319410.1021/acs.jmedchem.2c0188236821822
     [Google Scholar]
  81. CecchiniC. PannilunghiS. TardyS. ScapozzaL. From conception to development: Investigating PROTACs features for improved cell permeability and successful protein degradation.Front Chem.2021967226710.3389/fchem.2021.67226733959589
     [Google Scholar]
  82. HanL. JiangC. Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.Acta Pharm. Sin. B20211182306232510.1016/j.apsb.2020.11.02334522589
     [Google Scholar]
  83. LuB. YeJ. Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity.Acta Pharm. Sin. B202111103335333610.1016/j.apsb.2021.07.01734729320
     [Google Scholar]
  84. SamarasingheK.T.G. CrewsC.M. Targeted protein degradation: A promise for undruggable proteins.Cell Chem. Biol.202128793495110.1016/j.chembiol.2021.04.01134004187
     [Google Scholar]
  85. AshiqueS. AnandK. Radiolabelled extracellular vesicles as imaging modalities for precise targeted drug delivery.Pharmaceutics2023155142610.3390/pharmaceutics1505142637242668
     [Google Scholar]
  86. StewartM.P. LangerR. JensenK.F. Intracellular delivery by membrane disruption: Mechanisms, strategies, and concepts.Chem. Rev.2018118167409753110.1021/acs.chemrev.7b0067830052023
     [Google Scholar]
  87. BholeR.P. KuteP.R. ChikhaleR.V. BondeC.G. PantA. GuravS.S. Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy.Bioorg. Chem.202313910672010.1016/j.bioorg.2023.10672037480814
     [Google Scholar]
  88. LiS. ChenT. LiuJ. ZhangH. LiJ. WangZ. ShangG. PROTACs: Novel tools for improving immunotherapy in cancer.Cancer Lett.202356021612810.1016/j.canlet.2023.21612836933781
     [Google Scholar]
  89. SincereN.I. AnandK. AshiqueS. YangJ. YouC. PROTACs: Emerging targeted protein degradation approaches for advanced druggable strategies.Molecules20232810401410.3390/molecules2810401437241755
     [Google Scholar]
  90. RuffilliC. RothS. RodrigoM. BoydH. ZelcerN. MoreauK. Proteolysis targeting chimeras (PROTACs): A perspective on integral membrane protein degradation.ACS Pharmacol. Transl. Sci.202251084985810.1021/acsptsci.2c0014236268122
     [Google Scholar]
  91. KumarP. SharmaH. SinghA. DurgapalS. KukretiG. BhowmickM. BhowmickP. AshiqueS. Targeting the interplay of proteins through protacs for management cancer and associated disorders.Curr. Cancer Ther. Rev.2024209244910.2174/0115733947304806240417092449
     [Google Scholar]
/content/journals/cis/10.2174/012210299X306297240726094157
Loading
Integral Membrane Protein Degradation: A Novel Paradigm by PROTAC Technology
Curr. Indian Sci. 2, e2210299X306297 (2024); https://doi.org/10.2174/012210299X306297240726094157
/content/journals/cis/10.2174/012210299X306297240726094157
/content/journals/cis/10.2174/012210299X306297240726094157
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Autophagy; Integral membrane protein; PROTAC; Protein degradation; Proteolysis; Ubiquitin ligases

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test